SRSF1 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia, overexpression of SRSF1 resulted in impaired imatinib sensitivity via BCR-ABL1 and cytokine-mediated signaling pathways [24].